Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 17, 2026, Avantor, Inc. (the “Company”) informed Benoit Gourdier, the Company’s Executive Vice President, Bioscience and Medtech Products, that he would be transitioning to a new role supporting the Company’s segment integration activities, after which it is expected that he would depart the Company no later than December 31, 2026.
AVTR Avantor, Inc. - 8-K
Accession
0001628280-26-0269055.027.019.01
Item 5.02 - Departure/Election of Directors or Certain Officers
72 words
Item 7.01 - Regulation FD Disclosure
136 words
Item 7.01. Regulation FD Disclosure. On April 23, 2026, the Company issued a press release announcing the hiring of Ludovic Brellier to serve as the Company’s Executive Vice President, Bioscience and Medtech Products and Chief Transformation Officer effective May 1, 2026. A copy of the press release is furnished herewith as Exhibit No. 99 to this Current Report on Form 8-K, and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be deemed to be incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 - Financial Statements and Exhibits
33 words
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99 Press Release, dated April 23, 2026 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL